153 related articles for article (PubMed ID: 23653275)
21. Metabolic features of polycystic ovary syndrome are found in adolescent girls with hyperandrogenism.
Apter D; Bützow T; Laughlin GA; Yen SS
J Clin Endocrinol Metab; 1995 Oct; 80(10):2966-73. PubMed ID: 7559882
[TBL] [Abstract][Full Text] [Related]
22. Ovarian Hyperandrogenism and Response to Gonadotropin-releasing Hormone Analogues in Primary Severe Insulin Resistance.
Huang-Doran I; Kinzer AB; Jimenez-Linan M; Thackray K; Harris J; Adams CL; de Kerdanet M; Stears A; O'Rahilly S; Savage DB; Gorden P; Brown RJ; Semple RK
J Clin Endocrinol Metab; 2021 Jul; 106(8):2367-2383. PubMed ID: 33901270
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic criteria for polycystic ovary syndrome and ovarian morphology in women with type 1 diabetes mellitus.
Codner E; Soto N; Lopez P; Trejo L; Avila A; Eyzaguirre FC; Iniguez G; Cassorla F
J Clin Endocrinol Metab; 2006 Jun; 91(6):2250-6. PubMed ID: 16569737
[TBL] [Abstract][Full Text] [Related]
24. Prevalence of polycystic ovarian syndrome in Indian adolescents.
Nidhi R; Padmalatha V; Nagarathna R; Amritanshu R
J Pediatr Adolesc Gynecol; 2011 Aug; 24(4):223-7. PubMed ID: 21600812
[TBL] [Abstract][Full Text] [Related]
25. Serum HLA-G levels in women with polycystic ovary syndrome.
Oztekin O; Fenkci SM; Fenkci V; Enli Y; Cabus U
Gynecol Endocrinol; 2015 Mar; 31(3):243-6. PubMed ID: 25403326
[TBL] [Abstract][Full Text] [Related]
26. Hyperandrogenism in women with polycystic ovary syndrome persists after menopause.
Markopoulos MC; Rizos D; Valsamakis G; Deligeoroglou E; Grigoriou O; Chrousos GP; Creatsas G; Mastorakos G
J Clin Endocrinol Metab; 2011 Mar; 96(3):623-31. PubMed ID: 21177795
[TBL] [Abstract][Full Text] [Related]
27. Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome.
Barber TM; Wass JA; McCarthy MI; Franks S
Clin Endocrinol (Oxf); 2007 Apr; 66(4):513-7. PubMed ID: 17371468
[TBL] [Abstract][Full Text] [Related]
28. [Ovarian hyperandrogenism in adolescent girls with menstrual disorders].
Małecka-Tendera E; Zachurzok A; Wrześniewski N; Kurkowska M
Ginekol Pol; 2002 Feb; 73(2):93-101. PubMed ID: 12001778
[TBL] [Abstract][Full Text] [Related]
29. 17-hydroxyprogesterone responses to gonadotropin-releasing hormone disclose distinct phenotypes of functional ovarian hyperandrogenism and polycystic ovary syndrome.
Pasquali R; Patton L; Pocognoli P; Cognigni GE; Gambineri A
J Clin Endocrinol Metab; 2007 Nov; 92(11):4208-17. PubMed ID: 17785360
[TBL] [Abstract][Full Text] [Related]
30. Androgen levels and metabolic parameters are associated with a genetic variant of F13A1 in women with polycystic ovary syndrome.
Schweighofer N; Lerchbaum E; Trummer O; Schwetz V; Pilz S; Pieber TR; Obermayer-Pietsch B
Gene; 2012 Aug; 504(1):133-9. PubMed ID: 22565190
[TBL] [Abstract][Full Text] [Related]
31. Body mass index and ovarian function are associated with endocrine and metabolic abnormalities in women with hyperandrogenic syndrome.
Cupisti S; Kajaia N; Dittrich R; Duezenli H; W Beckmann M; Mueller A
Eur J Endocrinol; 2008 May; 158(5):711-9. PubMed ID: 18426831
[TBL] [Abstract][Full Text] [Related]
32. Hormonal profile in women with polycystic ovarian syndrome with or without type 1 diabetes mellitus.
Codner E; Iñíguez G; Villarroel C; Lopez P; Soto N; Sir-Petermann T; Cassorla F; Rey RA
J Clin Endocrinol Metab; 2007 Dec; 92(12):4742-6. PubMed ID: 17895317
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic value of calculated testosterone indices in the assessment of polycystic ovary syndrome.
Hahn S; Kuehnel W; Tan S; Kramer K; Schmidt M; Roesler S; Kimmig R; Mann K; Janssen OE
Clin Chem Lab Med; 2007; 45(2):202-7. PubMed ID: 17311509
[TBL] [Abstract][Full Text] [Related]
34. Insulin-like factor 3: a new circulating hormone related to luteinizing hormone-dependent ovarian hyperandrogenism in the polycystic ovary syndrome.
Gambineri A; Patton L; De Iasio R; Palladoro F; Pagotto U; Pasquali R
J Clin Endocrinol Metab; 2007 Jun; 92(6):2066-73. PubMed ID: 17356050
[TBL] [Abstract][Full Text] [Related]
35. Association between polycystic ovary syndrome and the risk of subclinical vascular disease in normal‑weight women with type 1 diabetes.
Łebkowska A; Adamska A; Jacewicz M; Tołwińska J; Krentowska A; Hryniewicka J; Leśniewska M; Bossowski A; Górska M; Kowalska I
Pol Arch Intern Med; 2017 Nov; 127(11):741-748. PubMed ID: 28972956
[TBL] [Abstract][Full Text] [Related]
36. Adrenal androgen excess and body mass index in polycystic ovary syndrome.
Moran C; Arriaga M; Arechavaleta-Velasco F; Moran S
J Clin Endocrinol Metab; 2015 Mar; 100(3):942-50. PubMed ID: 25514100
[TBL] [Abstract][Full Text] [Related]
37. Massive Ovarian Growth in a Woman With Severe Insulin-Resistant Polycystic Ovary Syndrome Receiving GnRH Analogue.
Singh P; Agress A; Madrigal VK; Magyar C; Ostrzega N; Chazenbalk GD; Dumesic DA
J Clin Endocrinol Metab; 2019 Jul; 104(7):2796-2800. PubMed ID: 30759233
[TBL] [Abstract][Full Text] [Related]
38. Lower insulin sensitivity differentiates hirsute from non-hirsute Sicilian women with polycystic ovary syndrome.
Amato MC; Galluzzo A; Merlino S; Mattina A; Richiusa P; Criscimanna A; Giordano C
Eur J Endocrinol; 2006 Dec; 155(6):859-65. PubMed ID: 17132756
[TBL] [Abstract][Full Text] [Related]
39. Hyperandrogenism, insulin resistance and hyperinsulinemia as cardiovascular risk factors in diabetes mellitus.
García-Romero G; Escobar-Morreale HF
Curr Diabetes Rev; 2006 Feb; 2(1):39-49. PubMed ID: 18220616
[TBL] [Abstract][Full Text] [Related]
40. Menstrual irregularity in the first postmenarchal years: an early clinical sign of polycystic ovary syndrome in adolescence.
Avvad CK; Holeuwerger R; Silva VC; Bordallo MA; Breitenbach MM
Gynecol Endocrinol; 2001 Jun; 15(3):170-7. PubMed ID: 11447727
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
